Illumina Instrumentation for Genomic Sequencing

Illumina is a U.S.-based company and a global leader in genomics, founded in 1998 and headquartered in San Diego, California. Thanks to a continuous focus on technological innovation, Illumina has revolutionized the landscape of genetic research and personalized medicine.

The company’s portfolio includes a wide range of integrated products and solutions for genome analysis, genotyping, and gene expression: among these are next-generation sequencing (NGS) platforms, microarray scanners, library preparation kits, reagents, and highly specialized software solutions such as BaseSpace and DRAGEN.

Illumina technologies ensure highly accurate data throughout the entire workflow, from sample preparation to bioinformatic analysis. The range includes compact and accessible systems like the MiSeq i100 Series, flexible benchtop solutions such as the NextSeq 1000/2000, and the high-throughput NovaSeq X Series, designed for large-scale genomic projects.

With a commercial presence in over 165 countries, a team of approximately 9,000 employees, and more than 22,000 installed instruments worldwide, Illumina supports laboratories, research centres, and clinical institutions in achieving advanced genomic discoveries. Through a commitment to quality, accessibility, and collaboration, the company drives progress in critical areas such as oncology, rare diseases, human reproduction, and infection monitoring.

Choosing the lease of Illumina technologies is a cost-effective option for laboratories. This approach allows continuous access to state-of-the-art instruments without the need for a significant upfront investment, facilitating more efficient cost management and ensuring regular technological updates. Furthermore, it is possible to take advantage of the tax deductibility of rental fees, a factor that contributes to making these activities more economically sustainable.